Orlem Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 1.00 M
- Company Age 15 Year, 11 Months
- Last Filing with ROC 31 Mar 2024
- Satisfied Charges ₹ 1.30 Cr
- Revenue Growth -29.96%
- Profit Growth 184.49%
- Ebitda -10.58%
- Net Worth 1.39%
- Total Assets -12.31%
About Orlem Pharma
Orlem Pharma Private Limited (OPPL) is a Private Limited Indian Non-Government Company incorporated in India on 19 February 2009 and has a history of 15 years and 11 months. Its registered office is in Ernakulam, Kerala, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M.
The company has closed loans amounting to ₹1.30 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Simon John and Baby Rani serve as directors at the Company.
Company Details
-
Location
Ernakulam, Kerala, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U52311KL2009PTC023846
-
Company No.
023846
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
19 Feb 2009
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Ernakulam
Industry
Who are the key members and board of directors at Orlem Pharma?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Simon John
|
Director | 19-Feb-2009 | Current |
|
Baby Rani
|
Director | 19-Feb-2009 | Current |
Financial Performance of Orlem Pharma.
Orlem Pharma Private Limited, for the financial year ended 2021, experienced significant reduction in revenue, with a 29.96% decrease. The company also saw a substantial improvement in profitability, with a 184.49% increase in profit. The company's net worth moved up by a moderate rise of 1.39%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Orlem Pharma?
In 2021, Orlem Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹0
₹13.00 M
Charges Breakdown by Lending Institutions
- Others : 1.15 Cr
- The South Indian Bank Limited : 0.15 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 22 Feb 2022 | Others | ₹2.50 M | Satisfied |
| 26 Dec 2012 | Others | ₹9.00 M | Satisfied |
| 16 Nov 2010 | The South Indian Bank Limited | ₹1.50 M | Satisfied |
How Many Employees Work at Orlem Pharma?
Unlock and access historical data on people associated with Orlem Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Orlem Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Orlem Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
